^
Association details:
| Biomarker: | FGFR mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
Published date:
08/31/2021
Excerpt:
Partial responses were observed in 1 from 12 patients. Median PFS was 2.4 months and median OS was 15.7 months….Ponatinib as a single agent in FGFR altered BTC is tolerable with limited clinical activity.
DOI:
10.1007/s10637-021-01170-x
